Biotech Values

[dav1234]

Kamada jumps on inhaled Antitrypsin speculation
Kamada (KMDA +1.5%) rises as investors anticipate results from a European trial of an inhaled version of Antitrypsin, an AAT treatment. See profile on KMDA's website.The Phase II/III study is scheduled to be completed by year-end.Here's Jefferies Raj Denhoy (as quoted by Bloomberg): “If the trial is successful, and I think there is a pretty good chance for it to be a success, Kamada will have the only inhalable version of the drug on the market."Jefferies estimate: $800M/year globally.